OBJECTIVE: To determine the T cell receptor (TCR) structure recognizing type II collagen (CII) in HLA-DR-transgenic mice, and to examine the role of T cells with certain V(beta)-chains in collagen-induced arthritis (CIA). METHODS: T cell hybridomas were established from DR1- and DR4-transgenic mice and selected for their responses to CII and CII peptide containing the T cell determinants. RNA was extracted and reverse transcribed into complementary DNA, which was then amplified using appropriate V(beta)- and V(alpha)-subfamily-specific primers. The polymerase chain reaction products were purified and directly sequenced. To determine the role of T cells with certain V(beta)-chains in CIA, V(beta)-subfamily-specific antibodies were administered and the development and characteristics of arthritis were determined. RESULTS: TCRs of 23 clonally distinct T cell hybridomas that were derived from DR1-transgenic mice and that were reactive to the CII peptide containing the immunodominant determinant were analyzed. These hybridomas predominantly used the TCR V(beta)14 and V(beta)8 gene segments (70% and 30%, respectively). The same restriction in V(beta) usage was also found in CII-reactive T cell hybridomas from DR4-transgenic mice. There was also restricted use of V(alpha) genes, although this was less marked than that of V(beta). In contrast, the hybridomas expressed a diverse third complementarity-determining region. Deletion of both V(beta)14-bearing and V(beta)8-bearing T cells significantly reduced the incidence and severity of CIA. CONCLUSION: These data demonstrate that DR1 and DR4 not only bind and present the same CII immunodominant peptide, but also stimulate a highly restricted subset of T cells.
OBJECTIVE: To determine the T cell receptor (TCR) structure recognizing type II collagen (CII) in HLA-DR-transgenic mice, and to examine the role of T cells with certain V(beta)-chains in collagen-induced arthritis (CIA). METHODS: T cell hybridomas were established from DR1- and DR4-transgenic mice and selected for their responses to CII and CII peptide containing the T cell determinants. RNA was extracted and reverse transcribed into complementary DNA, which was then amplified using appropriate V(beta)- and V(alpha)-subfamily-specific primers. The polymerase chain reaction products were purified and directly sequenced. To determine the role of T cells with certain V(beta)-chains in CIA, V(beta)-subfamily-specific antibodies were administered and the development and characteristics of arthritis were determined. RESULTS: TCRs of 23 clonally distinct T cell hybridomas that were derived from DR1-transgenic mice and that were reactive to the CII peptide containing the immunodominant determinant were analyzed. These hybridomas predominantly used the TCR V(beta)14 and V(beta)8 gene segments (70% and 30%, respectively). The same restriction in V(beta) usage was also found in CII-reactive T cell hybridomas from DR4-transgenic mice. There was also restricted use of V(alpha) genes, although this was less marked than that of V(beta). In contrast, the hybridomas expressed a diverse third complementarity-determining region. Deletion of both V(beta)14-bearing and V(beta)8-bearing T cells significantly reduced the incidence and severity of CIA. CONCLUSION: These data demonstrate that DR1 and DR4 not only bind and present the same CII immunodominant peptide, but also stimulate a highly restricted subset of T cells.
Authors: Katherine A Richards; Francisco A Chaves; Frederick R Krafcik; David J Topham; Christopher A Lazarski; Andrea J Sant Journal: J Virol Date: 2007-05-16 Impact factor: 5.103
Authors: Bo Tang; Seunghyun Kim; Sarah Hammond; David L Cullins; David D Brand; Edward F Rosloniec; John M Stuart; Arnold E Postlethwaite; Andrew H Kang; Linda K Myers Journal: Arthritis Res Ther Date: 2014-01-10 Impact factor: 5.156
Authors: Diahann T S L Jansen; Nishta Ramnoruth; Khai L Loh; Jamie Rossjohn; Hugh H Reid; Hendrik J Nel; Ranjeny Thomas Journal: Front Immunol Date: 2018-01-22 Impact factor: 7.561
Authors: Bernhard Knapp; Gottfried Fischer; Dries Van Hemelen; Ingrid Fae; Bernard Maillere; Christof Ebner; Wolfgang Schreiner; Barbara Bohle; Beatrice Jahn-Schmid Journal: BMC Immunol Date: 2012-08-08 Impact factor: 3.615